Atlas Venture Announces Andrea Armstrong Joins as Chief Talent Officer

Published: Jun 05, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Atlas Venture, a leading early stage biotech venture capital firm, today announced that Andrea Armstrong has joined as chief talent officer. Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.

"Talented individuals drive innovation and are the strength and vibrancy of the biotech industry. I was drawn to Atlas’ model of identifying cutting-edge science and partnering with entrepreneurs at the earliest stages to create transformational biotechs,” said Armstrong. “I couldn’t be more excited to be at Atlas, building exceptional teams that will develop breakthrough medicines.“

Armstrong joins Atlas from C4 Therapeutics, where she helped lead the organization through her role as chief administrative officer, with responsibility for human resources, talent acquisition and a variety of other operational functions. Prior to C4, Andrea was chief human resources officer and vice president of administration at the New York Genome Center where she led talent acquisition and recruited 125 people over two and a half years. Earlier in her career, Armstrong led recruiting for Infinity Pharmaceuticals and was a vice president at D.P. Parker & Associates, specializing in life sciences senior recruitment.

“Andrea is an accomplished biotech leader with a demonstrated ability to identify and recruit exceptional individuals to key roles in emerging companies," said David Grayzel, partner at Atlas Venture. “We are thrilled to welcome Andrea to Atlas and look forward to working with her to create the next generation of great biotechs."

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.

 

Contacts

Media:
Atlas Venture
Kristen Margeson, 857-201-2700
Director of Investor Relations and Marketing
lifesciences@atlasventure.com

 
 

Source: Atlas Venture

Back to news